2. Search Result
Search Result
Results for "

pkmyt1+inhibitor

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-145817A
    lunresertib
    5+ Cited Publications

    RP-6306

    		 Wee1 Cancer
    lunresertib (RP-6306) is a potent, selective and orally active PKMYT1 inhibitor with an IC50 of 14 nM. lunresertib shows a high degree of selectivity over other kinases in cellular binding assays. lunresertib shows anticancer effects [1].
    lunresertib
  • HY-145817
    (Rac)-lunresertib

    (Rac)-RP-6306

    		 Wee1 Cancer
    (Rac)-lunresertib (compound 181) is a potent membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) (Gene name PKMYT1) inhibitor with an IC50 of <10 nM. (Rac)-lunresertib (compound 181) has anticancer effects [1].
    (Rac)-lunresertib
  • HY-169946
    WEE1/PKMYT1-IN-1

    		Wee1 Cancer
    WEE1/PKMYT1-IN-1 (compound 75) is a potent and orally active WEE1 and PKMYT1 inhibitor. WEE1/PKMYT1-IN-1 shows antiproliferation activity [1].
    WEE1/PKMYT1-IN-1
  • HY-145817B
    (R)-lunresertib

    (R)-RP-6306

    		 Wee1 Cancer
    (R)-lunresertib is a membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) (Gene name PKMYT1) inhibitor, with IC50 of 1360 nM. (R)-lunresertib can be used in the study of Myt1-mediated cancers [1].
    (R)-lunresertib
  • HY-145664
    Myt1-IN-1

    		Wee1 Cancer
    Myt1-IN-1 is a potent membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) (Gene name PKMYT1) inhibitor with an IC50 of <10 nM. Myt1-IN-1 has anticancer effects (WO2021195782A1; compound 132) [1].
    Myt1-IN-1
  • HY-175819
    PD-166285

    		Wee1 Apoptosis Cancer
    PD-166285 is a PKMYT1 inhibitor, with an IC50 value of 17 nM. PD166285 shows strong antiproliferative effects against CCNE1-amplified OVCAR3 cells (IC50 = 0.14 μM) and HCC1569 cells (IC50 = 0.21 μM). PD166285 induces apoptosis and arrests CCNE1-amplified HCC1569 cells at the G1/S phase of the cell cycle. PD166285 can be used for the research of PKMYT1-targeted therapies for CCNE1-amplified cancers [1].
    PD-166285
  • HY-163491
    PKMYT1-IN-2

    		Wee1 Cancer
    PKMYT1-IN-2 (compound 2) is a potent PKMYT1 inhibitor with an IC50 of 5.7 nM. PKMYT1-IN-2 inhibits the growth of HCC1569 cells with an IC50 of 22 nM [1].
    PKMYT1-IN-2
  • HY-162988
    Myt1-IN-5

    		Wee1 Cancer
    Myt1-IN-5 (compound 4) is a membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) (Gene name PKMYT1) inhibitor with an IC50 of less than 200 nM.
    Myt1-IN-5
  • HY-145666
    Myt1-IN-3

    		Wee1 Cancer
    Myt1-IN-3 is a potent membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) (Gene name PKMYT1) inhibitor with an IC50s of <10 nM (WO2021195782 A1, compound 95) [1].
    Myt1-IN-3
  • HY-172759
    PKMYT1-IN-9

    		Wee1 Cancer
    PKMYT1-IN-9 is a highly selective and orally active PKMYT1 inhibitor (IC50: 4.4 nM). PKMYT1-IN-9 shows more selective for PKMYT1 than WEE1 (IC50: 32.4 μM). PKMYT1-IN-9 exhibits antitumor activity [1].
    PKMYT1-IN-9
  • HY-145665
    Myt1-IN-2

    		Wee1 Cancer
    Myt1-IN-2 is a potent membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) (Gene name PKMYT1) inhibitor with an IC50 of <10 nM. Myt1-IN-2 has anticancer effects (WO2021195782A1; compound 28) [1].
    Myt1-IN-2
  • HY-169946A
    WEE1/PKMYT1-IN-2

    		Wee1 Cancer
    WEE1/PKMYT1-IN-2 is the axial chiral P configuration of WEE1/PKMYT1-IN-1 (HY-169946). WEE1/PKMYT1-IN-1 is a potent and orally active WEE1 and PKMYT1 inhibitor. WEE1/PKMYT1-IN-1 shows antiproliferation activity [1].
    WEE1/PKMYT1-IN-2
  • HY-169946B
    WEE1/PKMYT1-IN-3

    		Wee1 Cancer
    WEE1/PKMYT1-IN-3 is the axial chiral M configuration of WEE1/PKMYT1-IN-1 (HY-169946). WEE1/PKMYT1-IN-1 is a potent and orally active WEE1 and PKMYT1 inhibitor. WEE1/PKMYT1-IN-1 shows antiproliferation activity [1].
    WEE1/PKMYT1-IN-3
  • HY-175817
    PKMYT1-IN-10

    		Wee1 Apoptosis Cancer
    PKMYT1-IN-10 is a selective PKMYT1 inhibitor with an IC50 of 3 nM. PKMYT1-IN-10 inhibits colony formation, induces apoptosis, and induces S-phase cancer cell cycle arrest. PKMYT1-IN-10 exhibits liver microsomal stability, favorable plasma stability, minimal CYPs inhibition. PKMYT1-IN-10 can be used for the studies of ovarian cancer and breast cancer [1].
    PKMYT1-IN-10
  • HY-162987
    PKMYT1-IN-6

    		Wee1 Cancer
    PKMYT1-IN-6 (compund 98) is a PKMYT1 inhibitor with IC50 less than 50 nM [1].
    PKMYT1-IN-6
  • HY-162986
    PKMYT1-IN-4

    		Wee1 Cancer
    PKMYT1-IN-4 (compund 27) is a PKMYT1 inhibitor with IC50 less than 50 nM [1].
    PKMYT1-IN-4
  • HY-162849
    PKMYT1-IN-3

    		Wee1 Cancer
    PKMYT1-IN-3 (compound 8ma) is a potent and selective PKMYT1 inhibitor with an IC50 value of 16.5 nM. PKMYT1-IN-3 has antitumor activity [1].
    PKMYT1-IN-3
  • HY-157443
    Myt1-IN-4

    		Wee1 Cancer
    Myt1-IN-4 (21) is an orally active and selective membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) (Gene name PKMYT1) inhibitor, with an IC50 of 2.6 nM. Myt1-IN-4 (21) possesses antitumor activity [1].
    Myt1-IN-4
  • HY-159937
    PKMYT1-IN-7

    		Wee1 CDK Cancer
    PKMYT1-IN-7 (compound 7) is an orally active PKMYT1 inhibitor with IC50 values of 1.6 nM and 0.06 μM against of PKMYT1 and pCDK1, respectively. PKMYT1-IN-7 suppresses the phosphorylation of CDK1 at T14 and Y15. PKMYT1-IN-7 shows anticancer activity both < and < [1].
    PKMYT1-IN-7
  • HY-182791
    BAA-009

    		Wee1 Cancer
    BAA-009 is a selective and orally active PKMYT1 inhibitor with an IC50 of <50 nM. BAA-009 inhibits cancer cells proliferation and inhibits tumor growth in OVCAR3 xenograft mice. BAA-009 can be used for the research of cancer, such as ovarian cancer [1].
    BAA-009
  • HY-182790
    BAA-065

    		Wee1 Cancer
    BAA-065 is a selective and orally active PKMYT1 inhibitor with an IC50 of <50 nM. BAA-065 inhibits cancer cells proliferation, induces γH2AX expression and DNA damage. BAA-065 inhibits tumor growth in OVCAR3 xenograft mice. BAA-065 can be used for the research of cancer, such as ovarian cancer [1].
    BAA-065
  • HY-182906
    XL495

    		Wee1 CDK Cancer
    XL495 is an potent, selective and orally active PKMYT1 inhibitor. XL495 inhibits CDK1 Thr14 phosphorylation and induces KAP1 Ser824 phosphorylation in xenograft tumors. XL495 reduces tumor growth in colorectal and breast cancer xenograft models, and achieves tumor regression with DNA-damaging agents in colorectal cancer xenograft models. XL495 can be used for the research of cancer, such as breast cancer and colorectal cancer [1] .
    XL495
  • HY-176957
    PKMYT1-IN-11

    		Wee1 Cancer
    PKMYT1-IN-11 (Example 1) is a PKMYT1 inhibitor with an IC50 of 4.49 nM. PKMYT1-IN-11 inhibits the proliferation of HCC1569 cells. When combined with Gemcitabine (HY-17026), PKMYT1-IN-11 shows a significant anti-tumor effect in the OVCAR3 xenograft mouse model. PKMYT1-IN-11 can be used for the study of various cancers such as breast cancer and ovarian cancer [1].
    PKMYT1-IN-11
  • HY-180893
    XH-30

    		Wee1 Apoptosis Cancer
    XH-30 is a potent, selective, and orally active PKMYT1 inhibitor, with an IC50 of 4.1 nM. XH-30 suppresses the proliferation of P53-mutated triple-negative breast cancer (TNBC) cells by inducing G2/M phase release, DNA damage, and apoptosis. XH-30 demonstrates antitumor effects in an MDA-MB-231 mouse model. XH-30 can be used for P53-mutated TNBC research [1].
    XH-30
  • HY-183547
    WEE1/PKMYT1-IN-4

    		Wee1 CDK Cancer
    WEE1/PKMYT1-IN-4 is a selective WEE1/PKMYT1 inhibitor, with IC50 values of 0.185 μM and 2.2 nM for human WEE1 and PKMYT1, respectively. WEE1/PKMYT1-IN-4 inhibits phosphorylation of CDK1 at T14 and Y15, disrupting the G2/M cell cycle checkpoint. WEE1/PKMYT1-IN-4 can be used for the research of colorectal cancer and amplified breast cancer [1].
    WEE1/PKMYT1-IN-4
  • HY-181004
    PKMYT1-IN-13

    		CDK Cancer
    PKMYT1-IN-13 is a potent, orally active and selective PKMYT1 inhibitor that inhibits PKMYT1 with IC50 values < 10.0 nM in ADP-Glo assay and 19.9 nM in NanoBRET cellular assay. PKMYT1-IN-13 exhibits high selectivity over WEE1. PKMYT1-IN-13 shows selective antiproliferative activity in CCNE1-amplified cells, while showing minimal wild-type effects. PKMYT1-IN-13 shows antitumor efficacy in HCC1569 mouse xenografts. PKMYT1-IN-13 can be used for the research of CCNE1-amplified cancers, such as gastric, ovarian, and breast cancer [1].
    PKMYT1-IN-13

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: